Geminor M 2 Tablet PR is a combination oral antihyperglycemic agent containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. The combination of these two agents provides complementary mechanisms of action, making Geminor M 2 Tablet PR effective in patients inadequately controlled by diet, exercise, and monotherapy. This medication is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is important to monitor blood glucose levels regularly to assess therapeutic response and adjust dosage accordingly. Caution is advised in patients with renal or hepatic impairment, and contraindications include diabetic ketoacidosis and conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances and hypoglycemia. Geminor M 2 Tablet PR should be used under medical supervision, with periodic evaluation of renal function and glycemic status to ensure safety and efficacy in achieving optimal glycemic control.